Renal & Urology News includes a CME article in every print issue, which will also be available online.
Once you have read the CME article, click on the link at the beginning of each article to take the post-test.
To view the full RUN myCME page, click here.
By Arlene B. Chapman, MD, and Jared J. Grantham, MD, FACP
Distinguishing primary from secondary FSGS is crucial because the treatment approaches and therapeutic goals differ.
Confirmation of creatinine-based eGFR should be performed in select circumstances using, where appropriate, either measured GFR or cystatin C.
PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Elderly patients face greater perioperative risks and postoperative mortality.
The type and amount of ingested protein affects clinical outcomes such as protein-energy wasting, kidney function and even survival.
Keeping abreast of the most current treatments for idiopathic OAB can lead to improved outcomes and quality of life.
The first step in prevention is adequate and quantitative counseling regarding fluid intake, which is effective and inexpensive.
While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.
Treatment of LUTS secondary to BPH has evolved from surgical therapy to medical monotherapy, and now combination therapy.
Given the frequency with which these lesions are found, urologists and nephrologists should be familiar with their evaluation.
Emerging data suggest that thyroid hormone deficiency may be associated with greater cardiovascular morbidity and mortality in this population.
Urologists typically treat a renal cortical mass without biopsy, but this should be re-evaluated in the era of the incidental small renal cortical neoplasm.
Scientific speculation suggests that uremic toxins, viral mediators, and immune inhibition could play a role in malignant transformation.
It is hoped that selective screening, selective biopsy, and selective therapy will further decrease the morbidity associated with screening.
The routine incorporation of NMIBC clinical practice guidelines will reduce variation in care by closing the gap on inappropriate delivery, whether over- or underuse.
With increased incidence of obesity—and higher caloric and salt intake—in the general population, resistant hypertension is more prevalent than ever.
Given the intimate anatomical and physiological relationship of the adrenals to the kidney, an understanding of adrenal disease is imperative for urologists and nephrologists alike.
The management of patients with high-risk prostate cancer represents one of the biggest challenges today, with little consensus on optimal treatment.
Clinicians need to keep abreast of the most current treatment options for NGB, which can result in improved patient outcomes and quality of life.
Approximately 30%-50% of SLE patients have clinically evident renal disease at presentation, but renal involvement occurs in up to 60% of patients overall.
A case study involving a 58-year-old man with acute gout attacks and multiple comorbidities, including hypertension and hypercholesterolemia.
Pre-existing renal osteodystrophy at the time of transplantation, reduced renal function, and transplantation-specific therapies are the main contributing factors.
Diagnostics and treatment options for NGB are continually advancing, and clinicians need to remain up-to-date to accurately assess and optimally manage patients
A case study involving a 65-year-old man with chronic kidney disease and acute attacks of pain, swelling, and erythema in the first metatarsophalangeal joint.
A case study examines the treatment of hyperuricemia and gout in a 57-year-old postmenopausal renal transplant recipient with intermittent gout attacks.
Patients who undergo renal transplantation require complex care that involves a diligent, multidisciplinary approach.
Short-term outcomes from early institutional experiences have confirmed the safety and feasibility of RPN, even for anatomically complex tumors.
Gout is increasingly recognized in patients with chronic kidney disease, but the proper dosing regimen for traditional agents has not been well-studied in this patient group.
In determining prostate cancer treatment, physicians should discuss preferences, values, and expectations with patients, including life expectancy, adverse events, and costs
Therapeutic options for SIADH have been significantly enhanced with the introduction of specific vasopressin receptor antagonists
In select patients, use of intermittent therapy does not appear to negatively affect overall survival and is associated with fewer adverse events.
Etiology and treatment are clearly defined for infectious prostatic syndromes, but not for chronic pelvic pain syndrome.
The complex biological actions of vitamin D suggest its involvement in various pathologies. (This is the second of a two-part CME article.)
Research has shown that vitamin D deficiency has a role in the progressive loss of kidney function as well as increased mortality.
A history of prostate cancer has generally been a contraindication for testosterone therapy, but the clinical model may be changing.
Following a renal biopsy diagnosis of IgA nephropathy, clinicians need to estimate prognosis and design an appropriate short- and long-term treatment strategy.
Recent advances in understanding genetic changes associated with kidney tumor formation have led to new pathologic classifications.
This article addresses the issues that must be understood to navigate the scenario posed by patients that have had a prior negative biopsy.
The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease.